Indevus Reports Interim Review of NEBIDO Phase III Data Indicates Trial Is Likely to Succeed.

0 Comments | M2 Presswire, March, 2007

M2 PRESSWIRE-26 March 2007-News Flash: Indevus Reports Interim Review of NEBIDO Phase III Data Indicates Trial Is Likely to Succeed(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:26032007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets.

Today's activity on the markets has brought these companies to the attention of our research team. On the NASDAQ exchange Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)